Peter Voorhees, MD

The FDA approval of daratumumab and hyaluronidase-fihj for high-risk smoldering MM shifts care beyond watchful waiting, notes Peter Voorhees, MD.

Peter Voorhees, MD, explains how new daratumumab data shift smoldering multiple myeloma from watchful waiting to treatment.

Peter Voorhees, MD, emphasizes the importance of carefully determined early regimens for smoldering myeloma and involving patients in treatment decisions.

Peter Voorhees, MD, explains how daratumumab and hyaluronidase-fihj show superior efficacy in delaying progression of MM compared with active monitoring.